Non-Hodgkin Lymphoma - Pipeline Insight, 2024

This “Non-Hodgkin Lymphoma - Pipeline Insight, 2024,” report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in Non-Hodgkin Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Non-Hodgkin Lymphoma Understanding

Non-Hodgkin Lymphoma: Overview

Non-Hodgkin Lymphoma (NHL) is a type of cancer that affects the lymphatic system, usually found in the lymph nodes. NHL is not a single disease but rather a group of several closely related cancers, called lymphoid neoplasms. The most recent 2016 revision of the World Health Organization classification of lymphoid neoplasms estimates that there are at least 86 types of NHL. Although the various types of NHL share many common characteristics, they differ in certain features, including their appearance under the microscope, their molecular features and growth patterns, their impact on the body, and how they respond to different types of treatment. NHL is the seventh most common cancer affecting adults in the United States. The incidence of NHL in the United States nearly doubled between 1975 and 2013, and more than 72,000 new cases were estimated to be diagnosed in 2016. Common signs and symptoms of NHL include swelling of the lymph nodes (which is often but not always painless), fever, night sweats, unexplained weight loss, and lack of energy. It is important to note that most patients with these symptoms do not have lymphoma, as diseases or conditions not related to lymphoma may cause many of these symptoms. A good rule of thumb is to seek medical attention if any of the signs or symptoms last longer than two weeks, or sooner if the symptoms are severe enough to impact daily life.

Non-Hodgkin lymphoma arises either from B cells, T cells, or natural killer cells due to chromosomal translocation or mutation/deletion. Proto-oncogenes are activated by chromosomal translocation, and tumor suppressor genes are inactivated by chromosomal deletion or mutation. The t (14; 18) translocation is the most common chromosomal abnormality in Non-Hodgkin lymphoma. This translocation is most common in follicular lymphoma. The t (11; 14) translocation is associated with mantle cell lymphoma. This results in the overexpression of cyclin D1, a cell cycle regulator. The t (8; 14) translocation of c-myc and heavy chain Ig (14) is associated with Burkitt lymphoma. Alteration in BCL-2 and BCL-6 is associated with diffuse large B-cell lymphoma. Primary CNS lymphoma is mostly associated with HIV/AIDS.

Treatment of Non-Hodgkin lymphoma is based on the type, stage, histopathological features, and symptoms. The most common treatment includes chemotherapy, radiotherapy, immunotherapy, stem cell transplant, and in rare cases, surgery. Chemoimmunotherapy, i.e., rituximab, in combination with chemotherapy, is most commonly used. Radiation is the main treatment for early-stage (I, II). Stage II with bulky disease, stage III, and IV are treated with chemotherapy along with immunotherapy, targeted therapy, and in some cases, radiation therapy.

Non-Hodgkin Lymphoma - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Non-Hodgkin Lymphoma pipeline landscape is provided which includes the disease overview and Non-Hodgkin Lymphoma treatment guidelines. The assessment part of the report embraces, in depth Non-Hodgkin Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Non-Hodgkin Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Non-Hodgkin Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Non-Hodgkin Lymphoma.

Non-Hodgkin Lymphoma Emerging Drugs Chapters

This segment of the Non-Hodgkin Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Non-Hodgkin Lymphoma Emerging Drugs

Mosunetuzumab: Hoffmann-la RocheMosunetuzumab is an investigational, humanized, T-cell bispecific antibody designed to engage T cells and redirect their cytotoxic activity against malignant B cells. Mosunetuzumab simultaneously binds to CD3 epsilon (CD3e), a component of the T-cell receptor (TCR) complex, and to CD20, a B-cell surface protein expressed in a majority of B-cell malignancies. This results in crosslinking of the TCR, inducing downstream signaling events that lead to B-cell killing. Mosunetuzumab is equipped with structural features that promote T-cell recruitment and retention, resulting in an antitumor effect. In preclinical models, mosunetuzumab induced T-cell proliferation and B-cell death; furthermore, efficient B-cell killing was achieved at low effector-to-target (T cell:B cell) ratios. Use of mosunetuzumab in combination with PD-L1 inhibition may address adaptive immune resistance mechanisms to enhance anticancer activity against B-cell malignancies. The drug is being evaluated in Phase III Study to evaluate the efficacy and safety of Mosunetuzumab in combination with Polatuzumab Vedotin in comparison with rituximab in combination with gemcitabine plus oxaliplatin in participants with relapsed or refractory aggressive b-cell Non-Hodgkin's Lymphoma.

Tisagenlecleucel: NovartisTisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy that involves genetically modified autologous T cells isolated from each individual patient. The reprogramming of the patient's T cells uses a lentiviral vector to encode an anti-CD19 chimeric antigen receptor (CAR). The CAR is comprised of a murine single-chain antibody fragment (scFv) specific for CD19, followed by a CD8 hinge and transmembrane region that is fused to the intracellular signaling domains from 4-1BB (CD137) and CD3 zeta Label. These intracellular costimulatory signaling domains increase the expansion, longer-term persistence and potency of CAR T cells: the CD3 zeta component is critical for initiating T-cell activation and antitumor activity, while 4-1BB enhances the expansion and persistence of tisagenlecleucel {FDA Label, A20379]. Upon binding to CD19-expressing cells, the CAR transmits a signal to promote T-cell expansion, activation, target cell elimination, and persistence of the tisagenlecleucel cells. Currently, it is in Phase III stage of clinical trial evaluation to treat Non-Hodgkin Lymphoma.

Capivasertib: AstraZenecaCapivasertib binds to and inhibits all AKT isoforms. Inhibition of AKT prevents the phosphorylation of AKT substrates that mediate cellular processes, such as cell division, apoptosis, and glucose and fatty acid metabolism. Currently, it is in Phase II stage of clinical trial evaluation to treat Non-Hodgkin Lymphoma.

BI-1206: BioInventBI-1206 is a high-affinity monoclonal antibody that selectivity binds to Fc?RIIB (CD32B), the only inhibitory member of the Fc?R family. Fc?RIIB is overexpressed in several forms of NHL and overexpression has been associated with poor prognosis in difficult-to treat forms of NHL, such as mantle cell lymphoma. By blocking Fc?RIIB, BI-1206 is expected to recover and enhance the activity of rituximab or other anti-CD20 monoclonal antibodies in the treatment of these diseases. In January 2023, positive data was presented from the ongoing clinical Phase I/IIa study of BI-1206 in combination with rituximab for the treatment of non-Hodgkin’s lymphoma (NHL). Data suggest that BI-1206 restores activity of rituximab in relapsed NHL patients.

HMPL-760: HutchmedHMPL-760 is an investigational, highly selective, non-covalent, third-generation inhibitor of BTK, both wild-type and C481S mutant enzymes, with pre-clinical data suggesting high target specificity and higher potency versus first generation BTK inhibitors. BTK C481S mutation plays an important role in resistance to certain BTK inhibitors.

HMPL-760 is HUTCHMED’s eleventh innovative potential oncology drug candidate to enter clinical develop¬ment. HUTCHMED retains all rights to HMPL-760 worldwide. Currently, the drug is in the Phase I stage of its development for the treatment of non-Hodgkin’s lymphoma.

Non-Hodgkin Lymphoma: Therapeutic Assessment

This segment of the report provides insights about the different Non-Hodgkin Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Non-Hodgkin Lymphoma

There are approx. 200+ key companies which are developing the therapies for Non-Hodgkin Lymphoma. The companies which have their Non-Hodgkin Lymphoma drug candidates in the most advanced stage, i.e. phase III include, Hoffmann-la Roche.

Phases

This report covers around 220+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Non-Hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Non-Hodgkin Lymphoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Non-Hodgkin Lymphoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Non-Hodgkin Lymphoma drugs.

Non-Hodgkin Lymphoma Report Insights

• Non-Hodgkin Lymphoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Non-Hodgkin Lymphoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Non-Hodgkin Lymphoma drugs?
• How many Non-Hodgkin Lymphoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Non-Hodgkin Lymphoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Non-Hodgkin Lymphoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Non-Hodgkin Lymphoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Novartis
• AstraZeneca
• Genentech
• BioInvent
• Genmab
• SystImmune
• Nordic Nanovector
• Pacylex Pharmaceuticals
• Artiva Biotherapeutics, Inc.
• Chipscreen Biosciences, Ltd.
• Timmune Biotech Inc.
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Gilead Sciences
• Acerta Pharma BV
• Adagene Inc
• Conjupro Biotherapeutics, Inc.
• Rhizen Pharmaceuticals
• Juventas Cell Therapy Ltd.
• Incyte Corporation
• HUYA Bioscience International
• SecuraBio
• Genor Biopharma Co., Ltd.
• Kyowa Kirin Co., Ltd.
• Antengene Therapeutics Limited
• Regeneron Pharmaceuticals
• Jiangsu HengRui Medicine Co., Ltd.
• Xynomic Pharmaceuticals, Inc.
• BioTheryX, Inc.
• UWELL Biopharma
• Kronos Bio
• Bio-Thera Solutions
• Spectrum Pharmaceuticals, Inc.
• Aptose Biosciences Inc.
• Miltenyi Biomedicine GmbH
• Precision BioSciences, Inc.
• Teneobio, Inc.
• TCR2 Therapeutics
• IGM Biosciences, Inc.

Key Products

• Tisagenlecleucel
• Capivasertib
• Mosunetuzumab
• BI-1206
• GEN3009
• GNC-038
• Betalutin
• PCLX-001
• AB-101
• Chiauranib
• TriCAR-T-CD19
• PBCAR0191
• CG-806
• TNB-486
• MB-CART2019.1
• TC-110 T Cells
• TQB2303
• IGM-2323
• Magrolimab
• IGN002
• Abexinostat
• BTX-A51
• BAT4306F
• KB-0742
• Welgenaleucel
• SHR1459
• Odronextamab
• ATG-019
• Acalabrutinib
• ADG106
• GB226
• ME-401
• CPO107
• Tenalisib,
• Duvelisib
• CNCT19
• Tafasitamab
• HBI-8000

This product will be delivered within 1-3 business days.